{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T17:22:04Z","timestamp":1787419324688,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116962","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:08:44Z","timestamp":1784732924000},"page":"116962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Methodological considerations in the interpretation of ASCENT-03"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-2827","authenticated-orcid":false,"given":"Francesca","family":"Poggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2480-3855","authenticated-orcid":false,"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116962_bib1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116962_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116962_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf034","article-title":"Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States","volume":"30","author":"Punie","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116962_bib4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models","volume":"20","author":"Robins","year":"1991","journal-title":"Commun Stat Theory Methods"},{"key":"10.1016\/j.ejca.2026.116962_bib5","article-title":"NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching","author":"Latimer","year":"2014","journal-title":"Lond Natl Inst Health Care Excell"},{"key":"10.1016\/j.ejca.2026.116962_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13063-023-07412-y","article-title":"Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies","volume":"24","author":"Prasad","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ejca.2026.116962_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116962_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2026.116962_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2026.44.16_suppl.1001","volume":"44","author":"Hurvitz","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:22:24Z","timestamp":1787415744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":9,"alternative-id":["S0959804926007434"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116962","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological considerations in the interpretation of ASCENT-03","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116962"}}